5-Amino-1MQ sits in peptide catalogues, vendor blogs and research-chemical price lists. Chemically it does not belong there. It is a methylquinolinium salt — a small-molecule enzyme inhibitor — characterised as a selective, membrane-permeable blocker of nicotinamide N-methyltransferase (NNMT). The rodent metabolic dataset is internally consistent and more mechanistically specified than most grey-market “fat-loss peptides”. The human interventional column is empty. This explainer grades that literature and sets out the UK legal position. Nothing here is consumption, dosing or self-administration advice. Research-use-only framing applies throughout.

1. What 5-Amino-1MQ is — and is not

5-Amino-1MQ is 5-amino-1-methylquinolinium, a quaternary ammonium heterocycle. It is not a peptide: there is no amino-acid sequence, no ribosomal or solid-phase peptide synthesis origin, and no proteolytic maturation step. It was generated by structure-guided medicinal chemistry around a 1-methylquinolinium scaffold at the University of Texas Medical Branch. The 2017 structure–activity paper in the Journal of Medicinal Chemistry mapped how primary-amine substitutions on that scaffold produced potent NNMT inhibition;[1] the 2018 Biochemical Pharmacology follow-up selected the 5-amino analogue as a cell-permeable, selective tool compound and took it into diet-induced obese mice.[2]

That journal attribution matters. Secondary write-ups sometimes cite the 2018 work as Nature Communications. The primary paper is Neelakantan, Vance, Wetzel and colleagues, Biochemical Pharmacology 147:141–152 (PMID 29155147).[2] Kraus and colleagues’ 2014 Nature paper is a different study: adipocyte-specific genetic knockdown of NNMT, not administration of 5-amino-1MQ.[3]

Factually, then, 5-Amino-1MQ is a small-molecule NNMT inhibitor used in biochemical, cell and rodent research. It is not a growth-hormone fragment, not a GLP-1 analogue, not an NAD+ precursor, and not an MHRA-licensed medicine.

2. The NNMT target, as currently understood

NNMT is a cytosolic enzyme that transfers a methyl group from S-adenosylmethionine (SAM) to nicotinamide, producing 1-methylnicotinamide (1-MNA, also abbreviated MNA) and S-adenosylhomocysteine. The reaction sits at a junction of two pools that metabolic researchers care about: nicotinamide that would otherwise re-enter NAD+ salvage, and SAM that would otherwise support other methylation reactions. High NNMT activity therefore functions, in the language of the field, as a combined NAD+ and methyl-donor sink.[2][4]

The target, as distinct from this particular inhibitor, has human observational support. Kannt and colleagues, writing in Diabetologia in 2015, reported that NNMT mRNA in human white adipose tissue, and the plasma concentration of its product 1-MNA, associated with insulin resistance.[5] Kraus et al. had already shown that adipocyte-specific NNMT knockdown protected mice from diet-induced obesity.[3] Those two papers justify studying NNMT. They do not demonstrate that administering 5-Amino-1MQ does anything in people.

In cultured adipocytes, Neelakantan et al. (2018) reported that methylquinolinium NNMT inhibitors reduced intracellular 1-MNA, increased intracellular NAD+ and SAM, and suppressed lipogenesis. Parallel artificial membrane permeability (PAMPA) and Caco-2 assays showed that primary-amine-substituted methylquinolinium scaffolds crossed membranes by both passive and active transport. Selectivity screens did not detect meaningful inhibition of related SAM-dependent methyltransferases or of NAD+ salvage-pathway enzymes at the concentrations tested.[2] That is a clean tool-compound profile in vitro. It is not a human pharmacology.

3. Evidence grade

Grade: limited.

The preclinical package is stronger than anecdotal research-chemical marketing implies, and weaker than a drug-development package requires. Peptide Data grades 5-Amino-1MQ as limited because:

  • All efficacy claims for the compound itself come from rodent and cell studies, principally from one originating chemistry/pharmacology group and its collaborators.
  • There is no published randomised, or even uncontrolled, interventional study of exogenous 5-Amino-1MQ in humans.
  • There is no published human pharmacokinetic, safety or dose-finding dataset.
  • Human data exist for the target (adipose NNMT expression and plasma 1-MNA versus insulin resistance),[5] not for this inhibitor.

Limited is the correct ceiling. Observational human biology of NNMT does not promote the compound to moderate. Vendor catalogues that describe 5-Amino-1MQ as a peptide with a human fat-loss protocol are misstating both the chemistry and the evidence.

4. What the mouse data do and do not support

The 2018 diet-induced obesity study. Neelakantan et al. administered a potent methylquinolinium NNMT inhibitor systemically to mice maintained on a high-fat diet. Relative to vehicle, treated animals had significantly reduced body weight and white-adipose mass, smaller adipocytes, and lower plasma total cholesterol. Food intake did not differ, and the authors reported no observable adverse effects over the short study window.[2] The paper’s own conclusion is that the results “support development of small molecule NNMT inhibitors as therapeutics to reverse diet-induced obesity and validate NNMT as a viable target”. That is a target-validation claim in mice, not a clinical result.

Aged skeletal muscle. A 2019 Biochemical Pharmacology paper from the same group reported that a small-molecule NNMT inhibitor activated senescent muscle stem cells and improved regenerative capacity after injury in aged mice, with supporting shifts in NAD+/NADH redox state.[6] This is a separate indication, still entirely preclinical. It should not be collapsed into the obesity dataset or read as evidence for “longevity” use in humans.

Inhibitor plus diet. Sampson et al. (2021) and Dimet-Wiley et al. (2022) examined NNMT inhibition combined with a switch from a high-fat Western diet to a low-fat diet in diet-induced obese mice. In the 2022 Scientific Reports paper, the combination rapidly normalised whole-body adiposity and weight toward age-matched lean controls, whereas diet switch alone did not achieve that normalisation on the same timescale; the study’s primary question was whether the cecal microbiome of the combination group resembled that of lean animals.[7][8] Combination-with-diet findings cannot be attributed to the inhibitor in isolation, and they remain mouse findings.

What this does not support. It does not establish that 5-Amino-1MQ reduces fat mass in humans. It does not establish oral bioavailability, half-life, tissue distribution or a therapeutic window in humans. It does not establish long-term safety of NNMT inhibition, including downstream effects on the methylome. It does not make commercial research-chemical vials equivalent to the academic material used in Galveston. Mouse metabolic phenotypes fail in human translation often enough that a single-digit-week rodent study is a reason to run a trial, not a reason to skip one.

5. Pharmacokinetics: rat data only

Awosemo, Neelakantan and colleagues published, in 2021, a validated LC–MS/MS assay for 5-amino-1-methylquinolinium in rat plasma and used it for a pharmacokinetic and oral-bioavailability study.[9] Mean oral bioavailability in the rat was 38.4%. That paper is, as of this writing, the only peer-reviewed pharmacokinetic characterisation of the compound. There is no published human absorption, distribution, metabolism or excretion study, no subcutaneous-versus-oral comparison in any species that would justify a human route, and no ICH-compliant toxicology package in the public literature.

Community “protocols” that convert milligram-per-kilogram mouse or rat figures into a daily human milligram amount are informal allometry, not a characterised human dose. Peptide Data does not reproduce those figures. They have no basis in a published human pharmacokinetic study.

6. UK regulatory position

5-Amino-1MQ has no marketing authorisation from the Medicines and Healthcare products Regulatory Agency. It is not a UK prescription-only medicine with an approved indication. It is not listed as a controlled drug under the Misuse of Drugs Act 1971. That combination — unlicensed, uncontrolled — is the standard grey-area position for research chemicals sold to UK laboratories.

The legal line is presentation, not the research-use sticker. Under the Human Medicines Regulations 2012 and the Medicines Act 1968, a product presented for treating or preventing disease, or for restoring, correcting or modifying physiological function through a pharmacological action, is a medicinal product. Offering 5-Amino-1MQ with claims of fat loss, metabolic enhancement or NAD+ restoration for human use would engage that definition, regardless of how the vial is labelled. MHRA guidance on research-peptide (and research-chemical) labelling continues to apply: laboratory supply is one activity; medicinal supply is another.[10]

No NICE technology appraisal exists, because there is no licensed product to appraise. NHS commissioning is not a relevant question until there is a UK marketing authorisation. There is not one.

7. Analytical and catalogue caveats

Two catalogue problems recur.

First, class mislabelling. Vendors file 5-Amino-1MQ alongside BPC-157, AOD-9604 and other research peptides. Identity testing for a quinolinium salt is not identity testing for a peptide. A certificate of analysis that reports “peptide purity” by a method validated on polypeptides does not characterise this molecule. Researchers who need the compound should require a method-specified assay for 5-amino-1-methylquinolinium (as in the Awosemo LC–MS/MS work),[9] plus confirmation of the counter-ion, residual solvents and, for any in-vivo system, endotoxin.

Second, NNMT-inhibitor conflation. 5-Amino-1MQ is one NAM-competitive NNMT inhibitor among several tool compounds in the literature, including JBSNF-000088 and later tricyclic series.[4] Findings generated with a different scaffold should not be attributed to 5-Amino-1MQ, and vice versa. No NNMT inhibitor has an MHRA (or other major-regulator) marketing authorisation.

Where Peptide Data pages mention Peptide Biosciences or other vendors, that relationship is disclosed separately and does not change the evidence grade.

8. Bottom line

NNMT is a biochemically coherent metabolic target. 5-Amino-1MQ is a characterised small-molecule inhibitor of that target, not a peptide. The 2018 mouse obesity study, the 2019 aged-muscle study, and the 2021 rat pharmacokinetic assay are real papers with defined methods. None of them is a human trial. The MHRA has not authorised 5-Amino-1MQ as a medicine. Evidence grade stays limited. Research-use-only remains the only defensible frame.

This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research compounds discussed here are not licensed for human consumption in the UK.

This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.